Marc Martinell, PhD
Co-Founder & Chief Executive Officer
Minoryx is a clinical stage biotech company leading the development of new therapies for X-ALD and other Orphan CNS diseases, a group of rare diseases of genetic origin with a high unmet medical need. The company’s leading program, a differentiated PPAR gamma agonist (MIN-102; leriglitazone), is a candidate for X-linked Adrenoleukodystrophy that has successfully completed phase 1 clinical trials, and is now in a pivotal phase 2/3 trial in adult X-linked Adrenoleukodystrophy (X-ALD) patients with Adrenomyeloneuropathy (AMN) and phase 2 trial in Friedreich’s Ataxia (FRDA) . Minoryx harnesses its unique mechanism of action for potential use in X-ALD and FRDA, two genetic diseases characterized by progressive neurological deterioration with no available pharmacological treatment.
Minoryx is also working on expanding the use of MIN-102 into other CNS diseases.
One of the biggest assets of the company is our team, a group of professionals fully committed to the task of delivering new treatments for rare diseases.
Minoryx and their employees are absolutely dedicated to relieving people’s suffering from rare diseases, especially children and their families.
We innovate by exploiting state of the art technologies. We form synergistic partnerships for drug discovery and provide them with an environment which fosters creativity and open-mindedness.
We strive to provide life-changing treatments for diseases with highly unmet medical needs.